Skip to main content
S&P 5007,664.14+0.95%DOW52,587.23+1.00%NASDAQ26,367.46+1.10%BTC$76,987.00-0.31%ETH$2,536.62+2.82%GOLD$4,388.70-0.42%OIL$100.38-2.05%
Smart Investors Daily
PR

NASDAQ · PRDS

Pardes Biosciences, Inc.

Healthcare · Biotechnology

$2.18

Up+$0.02 (+0.93%)

Updated Sep 11, 2026, 6:57 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
135.19M
P/E ratio
-1.36
Dividend yield
0.00%
52-week range
— – —
Volume
2.15M
Avg. volume
597.4K

Price performance

PRDS price history

1M range · 0 trading sessions · Daily adjusted prices

PRDS does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest PRDS news

The latest Smart Investors Daily articles mentioning PRDS.

Stock researchCompany · Overview

PRDS research

Overview

Company profile and research snapshot.

Company profile

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
PRDS recent ratings
DateFirmRatingTarget
Jul 18, 2023JMP SecuritiesMarket Perform—
Apr 4, 2023SVB LeerinkMarket Perform—
Mar 15, 2023JMP SecuritiesMarket Outperform—
Jan 27, 2023SVB LeerinkOutperform—
Dec 13, 2022JMP SecuritiesMarket Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Aug 31, 2023

Pardes Biosciences Announces Closing of Tender Offer

CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully completed the previously announced tender offer to acquire all of Pardes’ outstanding shares of common stock for a per share price of (i) $2.13 in cash (the Cash Amount), plus (ii) a non-tradeable contingent value right (each, a CVR and each CVR together with the Cash Amount, the Offer Price) associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.

GlobeNewswire Inc. · Jul 17, 2023

Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights

CARLSBAD, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) today announced that it has entered into a definitive merger agreement whereby MediPacific, Inc. (Purchaser) will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amount of the Company’s net cash at closing, plus a non-tradeable contingent value right (the CVR) associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By